Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.
Lindskog M, Laurell A, Kjellman A, Melichar B, Rey PM, Zieliński H, Villacampa F, Bigot P, Zoltan B, Parikh O, Alba DV, Jellvert Å, Flaskó T, Gallardo E, Caparrós MJR, Purkalne G, Suenaert P, Karlsson-Parra A, Ljungberg B. Lindskog M, et al. Among authors: karlsson parra a. Eur Urol Open Sci. 2022 Apr 26;40:38-45. doi: 10.1016/j.euros.2022.03.012. eCollection 2022 Jun. Eur Urol Open Sci. 2022. PMID: 35638086 Free PMC article.
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A, Lönnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A. Laurell A, et al. Among authors: karlsson parra a. J Immunother Cancer. 2017 Jun 20;5:52. doi: 10.1186/s40425-017-0255-0. eCollection 2017. J Immunother Cancer. 2017. PMID: 28642820 Free PMC article. Clinical Trial.
Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors.
Fröbom R, Berglund E, Berglund D, Nilsson IL, Åhlén J, von Sivers K, Linder-Stragliotto C, Suenaert P, Karlsson-Parra A, Bränström R. Fröbom R, et al. Among authors: karlsson parra a. Cancer Immunol Immunother. 2020 Nov;69(11):2393-2401. doi: 10.1007/s00262-020-02625-5. Epub 2020 Jun 13. Cancer Immunol Immunother. 2020. PMID: 32535637 Free PMC article. Clinical Trial.
Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.
Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M. Fotaki G, et al. Among authors: karlsson parra a. Oncoimmunology. 2017 Dec 26;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. eCollection 2018. Oncoimmunology. 2017. PMID: 29399398 Free PMC article.
Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response.
Jin C, Ali A, Iskantar A, Fotaki G, Wang H, Essand M, Karlsson-Parra A, Yu D. Jin C, et al. Among authors: karlsson parra a. Oncoimmunology. 2022 Jul 13;11(1):2099642. doi: 10.1080/2162402X.2022.2099642. eCollection 2022. Oncoimmunology. 2022. PMID: 35859733 Free PMC article.
86 results